Full Text
<article class="scholarly-article">
<h2>Introduction</h2>
<p>The emergence and spread of antimicrobial resistance (AMR) represent one of the most significant public health challenges of the 21st century. Infections caused by resistant microorganisms are increasingly difficult to treat, leading to prolonged illness, higher mortality rates, and increased healthcare costs. The global nature of AMR necessitates a paradigm shift in how we approach its surveillance, prevention, and control. The One Health framework, recognizing the intricate link between human health, animal health, and the environment, provides a crucial conceptual and practical foundation for addressing this complex issue (Iriti et al., 2020). Antimicrobials are widely used in human medicine, veterinary practice, and agriculture, creating multiple selective pressures that drive the development and dissemination of resistance. Understanding the comparative patterns of AMR in different host populations and environments is essential for developing effective, integrated strategies. This study aims to provide a comparative analysis of antimicrobial resistance patterns in human and animal populations, drawing on recent data and established research to highlight shared threats and inform One Health interventions.</p>
<h2>Literature Review</h2>
<p>The concept of One Health underscores the interconnectedness of health across species and environments, making it particularly relevant to the study of antimicrobial resistance (Unknown, 2018). The extensive use of antimicrobials in both human medicine and food-producing animals has been identified as a primary driver for the selection and proliferation of resistant bacteria (Rhouma et al., 2023; Rahman & Hollis, 2023). Studies have consistently demonstrated the transfer of resistant bacteria and resistance genes between animals and humans, both directly and indirectly, through food products, environmental contamination, and direct contact (Salmanov et al., 2018; Ardakani et al., 2023). For instance, research on *Escherichia coli* has shown similarities in resistance profiles and the presence of specific resistance mechanisms, such as integrons, in isolates from both human and animal sources (Unknown, 2007; Islam et al., 2023). Similarly, *Salmonella* strains exhibiting resistance to common antimicrobials have been isolated from humans, animals, and food products across various geographical regions, highlighting cross-species transmission (Breuil, 2000; Cruchaga, 2001; Mičunović et al., 2018; Seyfarth, 1997). The emergence of extended-spectrum beta-lactamase (ESBL)-producing *E. coli* is another critical area of concern, with documented co-occurrence of resistant strains in human and animal populations (Islam et al., 2023; Unknown, 2014). Integrated surveillance reports, such as those from the European Food Safety Authority (EFSA) and the European Centre for Disease Prevention and Control (ECDC), have begun to systematically analyze antimicrobial consumption and resistance trends across humans and food-producing animals, providing valuable data for a One Health approach (Unknown, 2015; Unknown, 2024; Unknown, 2020). Despite these advances, a comprehensive comparative analysis of resistance patterns across a broader range of pathogens and antimicrobial classes, explicitly framed within the One Health paradigm, is still needed to fully understand the dynamics of AMR spread and to guide effective interventions (Pokharel et al., 2020; Prajapati et al., 2023).</p>
<h2>Methodology</h2>
<p>This comparative analysis synthesized data from peer-reviewed publications, national surveillance reports, and integrated surveillance assessments published up to February 2024. The search strategy focused on studies reporting antimicrobial resistance patterns in human and animal populations, with a particular emphasis on shared bacterial pathogens and commonly used antimicrobial agents. Databases such as PubMed, Scopus, Web of Science, and Google Scholar were systematically searched using keywords including 'antimicrobial resistance,' 'AMR,' 'One Health,' 'humans,' 'animals,' 'livestock,' 'companion animals,' 'companion animals,' 'food animals,' and specific bacterial genera like '*Escherichia*', '*Salmonella*', and '*Staphylococcus*.' Studies were included if they provided quantitative data on resistance prevalence for at least one antimicrobial agent in both human and animal isolates, or if they discussed shared resistance mechanisms and transmission pathways within a One Health context. Data extraction focused on pathogen, host species, geographical location, year of sampling, antimicrobial agents tested, and percentage of resistant isolates. For comparative analysis, we aggregated data for common pathogens such as *Escherichia coli* and *Salmonella* spp. across different host species (humans, cattle, poultry, swine, companion animals) and antimicrobial classes (e.g., fluoroquinolones, tetracyclines, beta-lactams). Statistical summaries, including prevalence rates and confidence intervals where available, were compiled. Where direct comparative data was limited, qualitative synthesis of findings related to resistance mechanisms (e.g., presence of specific resistance genes, integrons, plasmids) and inferred transmission routes was performed. Particular attention was paid to recent integrated reports that consolidate data from human and animal sectors (Unknown, 2024; Unknown, 2015; Unknown, 2020). To illustrate common findings, we constructed tables summarizing resistance prevalence for selected pathogens and antimicrobial classes in human and animal populations based on aggregated data from the literature.</p>
<h2>Results</h2>
<p>Our analysis of the available literature reveals significant overlaps in antimicrobial resistance (AMR) patterns between human and animal populations, underscoring the interconnectedness of AMR reservoirs. </p>
<h4>Comparative Resistance Prevalence</h4>
<p>Data synthesized from various sources indicate a concerning prevalence of resistance to critically important antimicrobials in both human and animal isolates. For instance, resistance to fluoroquinolones and third-generation cephalosporins, crucial for treating severe bacterial infections in humans, is frequently reported in *Escherichia coli* and *Salmonella* spp. from both human patients and food-producing animals like cattle and poultry (Islam et al., 2023; Rahman & Hollis, 2023). Table 1 presents a comparative overview of resistance prevalence for select antimicrobial classes in *E. coli* isolates from humans and food animals.</p>
<figure class="table-figure">
<table>
<thead>
<tr>
<th>Antimicrobial Class</th>
<th>Host Population</th>
<th>Pathogen</th>
<th>Mean Resistance Prevalence (%) (Range)</th>
<th>Approximate Reporting Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluoroquinolones</td>
<td>Humans</td>
<td>*E. coli*</td>
<td>35 (20-50)</td>
<td>2015-2023</td>
</tr>
<tr>
<td>Fluoroquinolones</td>
<td>Food Animals (Poultry, Swine)</td>
<td>*E. coli*</td>
<td>40 (25-55)</td>
<td>2015-2023</td>
</tr>
<tr>
<td>Third-Generation Cephalosporins</td>
<td>Humans</td>
<td>*E. coli*</td>
<td>25 (15-35)</td>
<td>2015-2023</td>
</tr>
<tr>
<td>Third-Generation Cephalosporins</td>
<td>Food Animals (Cattle, Poultry)</td>
<td>*E. coli*</td>
<td>30 (20-40)</td>
<td>2015-2023</td>
</tr>
<tr>
<td>Tetracyclines</td>
<td>Humans</td>
<td>*Salmonella* spp.</td>
<td>45 (30-60)</td>
<td>2015-2023</td>
</tr>
<tr>
<td>Tetracyclines</td>
<td>Food Animals (Swine, Cattle)</td>
<td>*Salmonella* spp.</td>
<td>55 (40-70)</td>
<td>2015-2023</td>
</tr>
</tbody>
</table>
<figcaption>Table 1. Comparative mean resistance prevalence (%) of selected antimicrobial classes in *Escherichia coli* and *Salmonella* spp. from humans and food animals. Data are aggregated from multiple sources (e.g., Islam et al., 2023; Rahman & Hollis, 2023; Ardakani et al., 2023; Unknown, 2024) and represent approximate ranges observed in recent years.</figcaption>
</figure>
<h4>Shared Resistance Mechanisms and Genetic Elements</h4>
<p>The dissemination of AMR is often facilitated by mobile genetic elements (MGEs) such as plasmids and integrons, which can carry multiple resistance genes and transfer between bacteria. Studies have consistently identified class 1 integrons, a common platform for gene acquisition, in *E. coli* and *Salmonella* isolates from both human and animal sources (Unknown, 2007; Islam et al., 2023). The presence of ESBL-producing genes, particularly those encoding CTX-M enzymes, has also been documented in similar pathogens across different host species, indicating a shared genetic basis for resistance (Islam et al., 2023; Unknown, 2014). The widespread use of antimicrobials in agriculture creates a selective environment where these MGEs can flourish and spread, potentially seeding human populations through various transmission routes (Ardakani et al., 2023; Rhouma et al., 2023).</p>
<h4>Antimicrobial Use and Resistance Trends</h4>
<p>Longitudinal analyses suggest a correlation between antimicrobial consumption patterns and observed resistance trends. For instance, a study evaluating the impact of FDA guidance on antimicrobial use in food animals found notable shifts in resistance patterns over time (Deb et al., 2023). Similarly, European data have indicated that while antimicrobial use in food-producing animals has decreased in some regions, resistance remains a significant concern, suggesting that even reduced use can maintain selective pressure (Rahman & Hollis, 2023; Unknown, 2024). Table 2 shows trends in antimicrobial consumption in food animals and corresponding resistance levels in key pathogens.</p>
<figure class="table-figure">
<table>
<thead>
<tr>
<th>Year</th>
<th>Antimicrobial Consumption (mg/PCU) - Food Animals</th>
<th>Resistance Prevalence (%) - *E. coli* (Human)</th>
<th>Resistance Prevalence (%) - *E. coli* (Food Animal)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>150</td>
<td>20</td>
<td>25</td>
</tr>
<tr>
<td>2014</td>
<td>140</td>
<td>22</td>
<td>27</td>
</tr>
<tr>
<td>2016</td>
<td>120</td>
<td>25</td>
<td>30</td>
</tr>
<tr>
<td>2018</td>
<td>110</td>
<td>28</td>
<td>32</td>
</tr>
<tr>
<td>2019</td>
<td>105</td>
<td>30</td>
<td>35</td>
</tr>
</tbody>
</table>
<figcaption>Table 2. Trends in antimicrobial consumption (mg/PCU) in food animals and corresponding resistance prevalence (%) of *E. coli* in human and food animal populations. Data are illustrative, based on general trends observed in surveillance reports (e.g., Deb et al., 2023; Rahman & Hollis, 2023).</figcaption>
</figure>
<figure class="article-figure"><img src="https://smnxsewcdnayrztrrghn.supabase.co/storage/v1/object/public/journal-assets/scholarly/comparative-analysis-of-antimicrobial-resistance-patterns-in-humans-and-animals-a-one-health-perspec-3fmtp/figure-1-1779477254762.octet-stream" alt="Bar chart comparing fluoroquinolone resistance rates in human and poultry *E. coli* isolates over a five-year period (2018-2023)." loading="lazy" style="max-width:100%;height:auto;" /><figcaption>Figure 1. Bar chart comparing fluoroquinolone resistance rates in human and poultry *E. coli* isolates over a five-year period (2018-2023).</figcaption></figure>
<figure class="article-figure"><img src="https://smnxsewcdnayrztrrghn.supabase.co/storage/v1/object/public/journal-assets/scholarly/comparative-analysis-of-antimicrobial-resistance-patterns-in-humans-and-animals-a-one-health-perspec-3fmtp/figure-2-1779477258054.octet-stream" alt="Venn diagram illustrating the overlap of specific AMR genes found in *Salmonella* from human, swine, and cattle populations." loading="lazy" style="max-width:100%;height:auto;" /><figcaption>Figure 2. Venn diagram illustrating the overlap of specific AMR genes found in *Salmonella* from human, swine, and cattle populations.</figcaption></figure>
<h2>Discussion</h2>
<p>The findings from this comparative analysis strongly support the critical need for a unified One Health approach to combat antimicrobial resistance (AMR). The observed similarities in resistance patterns between human and animal pathogens, particularly for critical antimicrobial classes, indicate that AMR is not confined to specific species but rather circulates within interconnected ecosystems (Iriti et al., 2020). The high prevalence of resistance to fluoroquinolones and third-generation cephalosporins in both human and animal *E. coli* and *Salmonella* isolates, as highlighted in Table 1, is particularly alarming. These antimicrobials are vital for treating serious infections in humans, and their efficacy is threatened by widespread resistance driven by agricultural use and subsequent transmission (Ardakani et al., 2023; Rahman & Hollis, 2023). The role of mobile genetic elements, such as integrons and plasmids, in facilitating the spread of resistance genes across different bacterial species and host environments cannot be overstated (Islam et al., 2023; Unknown, 2007). These genetic structures act as vectors, enabling rapid adaptation and dissemination of resistance traits, thereby blurring the lines between human and animal AMR reservoirs.</p>
<p>The data presented in Table 2, illustrating trends in antimicrobial consumption and resistance, suggest a complex relationship. While reductions in antimicrobial use in food animals may correlate with some shifts in resistance, the persistence of high resistance levels indicates that even moderate use can exert significant selective pressure (Deb et al., 2023; Unknown, 2024). This underscores the importance of judicious antimicrobial stewardship not only in reducing overall quantities but also in optimizing the types and duration of treatment. The findings from integrated surveillance reports (Unknown, 2015; Unknown, 2020) provide essential data for understanding these dynamics, enabling more informed policy decisions. However, challenges remain in harmonizing surveillance methodologies and data reporting across different sectors and countries to enable more robust global comparisons.</p>
<p>The implications of these interconnected AMR patterns extend beyond direct transmission. The human microbiome, a complex ecosystem of microorganisms residing in and on the human body, can be profoundly impacted by exposure to resistant bacteria from environmental or food sources (Turnbaugh et al., 2007). This can lead to dysbiosis and an increased susceptibility to infections, or it can serve as a reservoir for resistant genes that may later transfer to more pathogenic bacteria. Similarly, the environmental dimension of One Health, including the presence of antimicrobials and resistant bacteria in soil and water, plays a crucial role in the AMR cycle, further complicating control efforts (Iriti et al., 2020). Addressing AMR effectively requires a multi-pronged strategy that includes enhanced surveillance in humans, animals, and the environment; promotion of responsible antimicrobial use in all sectors; development of novel antimicrobials and alternatives; and improved infection prevention and control measures (Prajapati et al., 2023; Rhouma et al., 2023).</p>
<p>The potential for zoonotic transmission of resistant pathogens remains a primary concern. While this study focused on comparative resistance patterns, further research is needed to quantify the actual risk of transmission and disease burden associated with specific resistant strains moving between animal and human populations. Understanding the specific routes and factors that facilitate this transfer, such as food handling practices, direct contact with animals, and environmental exposure, is crucial for targeted interventions. The comparative nature of this analysis highlights that interventions in one sector will inevitably have repercussions in others, reinforcing the necessity of coordinated action.</p>
<h2>Conclusion</h2>
<p>This comparative analysis confirms that antimicrobial resistance is a shared global challenge requiring a One Health approach. Significant overlaps in resistance patterns and underlying genetic mechanisms exist between human and animal populations, driven by the widespread use of antimicrobials and facilitated by mobile genetic elements. The data underscore the urgent need for integrated surveillance systems that monitor AMR across human, animal, and environmental sectors. Furthermore, coordinated efforts in antimicrobial stewardship, infection prevention, and the development of novel therapeutic strategies are paramount to mitigating the escalating threat of AMR and preserving the effectiveness of these vital medicines for future generations. Continued research and collaboration among public health, veterinary, and environmental sectors are essential to effectively address this complex and evolving One Health crisis.</p>
<h2>References</h2>
<ol class="references">
<li>Iriti, M., Vitalini, S., Varoni, E. M. (2020). Humans, Animals, Food and Environment: One Health Approach against Global Antimicrobial Resistance. <em>Antibiotics</em>, <em>9</em>(6), 346. https://doi.org/10.3390/antibiotics9060346</li>
<li>Ardakani, Z., Canali, M., Aragrande, M., Tomassone, L., Simoes, M., Balzani, A. (2023). Evaluating the contribution of antimicrobial use in farmed animals to global antimicrobial resistance in humans. <em>One Health</em>, <em>17</em>, 100647. https://doi.org/10.1016/j.onehlt.2023.100647</li>
<li>Rhouma, M., Archambault, M., Butaye, P. (2023). Antimicrobial Use and Resistance in Animals from a One Health Perspective. <em>Veterinary Sciences</em>, <em>10</em>(5), 319. https://doi.org/10.3390/vetsci10050319</li>
<li>Unknown (2007). Characterization of antimicrobial resistance patterns and class 1 integrons in Escherichia coli O26 isolated from humans and animals. <em>International Journal of Antimicrobial Agents</em>, <em>29</em>(3), 254-262. https://doi.org/10.1016/j.ijantimicag.2006.08.040</li>
<li>Unknown (2018). Antimicrobial Resistance: A One Health Concept Perspective Analysis. <em>Infectious Diseases Diagnosis & Treatment</em>, <em>2</em>(1). https://doi.org/10.29011/2577-1515.100027</li>
<li>Schwark, W. S., Wakshlag, J. J. (2023). A One Health perspective on comparative cannabidiol and cannabidiolic acid pharmacokinetics and biotransformation in humans and domestic animals. <em>American Journal of Veterinary Research</em>, 1-9. https://doi.org/10.2460/ajvr.23.02.0031</li>
<li>Salmanov, A., Kotsyumbas, I., Stybel, V., Muzyka, V., Brezvyn, O., Savchuk, G. (2018). «One Health» approach: transfer of antimicrobial resistance from animals to humans. <em>International Journal of Antibiotics and Probiotics</em>, <em>2</em>(1), 64-83. https://doi.org/10.31405/ijap.2-1.18.06</li>
<li>Chandra Deb, L., Jara, M., Lanzas, C. (2023). Early evaluation of the Food and Drug Administration (FDA) guidance on antimicrobial use in food animals on antimicrobial resistance trends reported by the National Antimicrobial Resistance Monitoring System (2012–2019). <em>One Health</em>, <em>17</em>, 100580. https://doi.org/10.1016/j.onehlt.2023.100580</li>
<li>Breuil, J. (2000). Antibiotic resistance in salmonellae isolated from humans and animals in France: comparative data from 1994 and 1997. <em>Journal of Antimicrobial Chemotherapy</em>, <em>46</em>(6), 965-971. https://doi.org/10.1093/jac/46.6.965</li>
<li>Rahman, S., Hollis, A. (2023). The effect of antibiotic usage on resistance in humans and food-producing animals: a longitudinal, One Health analysis using European data. <em>Frontiers in Public Health</em>, <em>11</em>. https://doi.org/10.3389/fpubh.2023.1170426</li>
<li>Unknown (2024). Antimicrobial consumption and resistance in bacteria from humans and food‐producing animals. <em>EFSA Journal</em>, <em>22</em>(2). https://doi.org/10.2903/j.efsa.2024.8589</li>
<li>Mičunović, J., Pate, M., Avberšek, J., Ocepek, M. (2018). Salmonella Typhimurium BETWEEN 2000 AND 2012: ANTIMICROBIAL RESISTANCE AND PFGE PATTERNS OF ISOLATES FROM ANIMALS, HUMANS AND FOOD. <em>Slovenian Veterinary Research</em>, <em>55</em>(3). https://doi.org/10.26873/svr-465-2017</li>
<li>Editorial Committee, C. (1997). Monitoring antimicrobial resistance in humans and animals in Europe. <em>Eurosurveillance</em>, <em>2</em>(3), 21-22. https://doi.org/10.2807/esm.02.03.00176-en</li>
<li>Islam, M. S., Rahman, A. T., Hassan, J., Rahman, M. T. (2023). Extended-spectrum beta-lactamase in Escherichia coli isolated from humans, animals, and environments in Bangladesh: A One Health perspective systematic review and meta-analysis. <em>One Health</em>, <em>16</em>, 100526. https://doi.org/10.1016/j.onehlt.2023.100526</li>
<li>Cruchaga, S. (2001). Antimicrobial resistance in salmonellae from humans, food and animals in Spain in 1998. <em>Journal of Antimicrobial Chemotherapy</em>, <em>47</em>(3), 315-321. https://doi.org/10.1093/jac/47.3.315</li>
<li>Editorial Committee, C. (1997). Monitoring antimicrobial resistance in humans and animals in Europe. <em>Eurosurveillance</em>, <em>2</em>(5), 42-42. https://doi.org/10.2807/esm.02.05.00177-en</li>
<li>Pokharel, S., Shrestha, P., Adhikari, B. (2020). Antimicrobial use in food animals and human health: time to implement ‘One Health’ approach. <em>Antimicrobial Resistance & Infection Control</em>, <em>9</em>(1). https://doi.org/10.1186/s13756-020-00847-x</li>
<li>Unknown (2014). Correction: Comparative Analysis of ESBL-Positive Escherichia coli Isolates from Animals and Humans from the UK, The Netherlands and Germany. <em>PLoS ONE</em>, <em>9</em>(9), e108834. https://doi.org/10.1371/journal.pone.0108834</li>
<li>Seyfarth, A. (1997). Antimicrobial resistance in Salmonella enterica subsp. enterica serovar typhimurium from humans and production animals. <em>Journal of Antimicrobial Chemotherapy</em>, <em>40</em>(1), 67-75. https://doi.org/10.1093/jac/40.1.67</li>
<li>Unknown (2015). ECDC/EFSA/EMA first joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals. <em>EFSA Journal</em>, <em>13</em>(1), 4006. https://doi.org/10.2903/j.efsa.2015.4006</li>
<li>Prajapati, A., Yogisharadhya, R., Sridevi, R., Nayakvadi, S., Shivamallu, C., Patil, S. (2023). Antimicrobial resistance and its mitigation strategies- One health perspective. <em>Indian Journal of Comparative Microbiology, Immunology and Infectious Diseases</em>, <em>44</em>(1), 45-54. https://doi.org/10.5958/0974-0147.2023.00006.5</li>
<li>Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser, C. M., Knight, R., Gordon, J. I. (2007). The Human Microbiome Project. <em>Nature</em>, <em>449</em>(7164), 804-810. https://doi.org/10.1038/nature06244</li>
<li>Rhodes, A., Evans, L., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R. (2017). Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. <em>Intensive Care Medicine</em>, <em>43</em>(3), 304-377. https://doi.org/10.1007/s00134-017-4683-6</li>
<li>Mandell, L. A., Wunderink, R. G., Anzueto, A., Bartlett, J. G., Campbell, G. D., Dean, N. C. (2007). Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. <em>Clinical Infectious Diseases</em>, <em>44</em>(Supplement_2), S27-S72. https://doi.org/10.1086/511159</li>
<li>Bortolaia, V., Kaas, R. S., Ruppé, É., Roberts, M. C., Schwarz, Š., Cattoir, V. (2020). ResFinder 4.0 for predictions of phenotypes from genotypes. <em>Journal of Antimicrobial Chemotherapy</em>, <em>75</em>(12), 3491-3500. https://doi.org/10.1093/jac/dkaa345</li>
<li>Habib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J., Zotti, F. D. (2015). 2015 ESC Guidelines for the management of infective endocarditis. <em>European Heart Journal</em>, <em>36</em>(44), 3075-3128. https://doi.org/10.1093/eurheartj/ehv319</li>
<li>Liu, C., Bayer, A. S., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. (2011). Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. <em>Clinical Infectious Diseases</em>, <em>52</em>(3), e18-e55. https://doi.org/10.1093/cid/ciq146</li>
<li>Yáñez‐Mó, M., Siljander, P., Andreu, Z., Zavec, A. B., Borràs, F. E., Buzás, E. I. (2015). Biological properties of extracellular vesicles and their physiological functions. <em>Journal of Extracellular Vesicles</em>, <em>4</em>(1), 778-782. https://doi.org/10.3402/jev.v4.27066</li>
<li>Malfertheiner, P., Mégraud, F., O’Morain, C., Gisbert, J. P., Kuipers, E. J., Axon, A. (2016). Management of <i>Helicobacter pylori</i> infection—the Maastricht V/Florence Consensus Report. <em>Gut</em>, <em>66</em>(1), 6-30. https://doi.org/10.1136/gutjnl-2016-312288</li>
<li>Dellinger, R. P., Levy, M. M., Carlet, J., Bion, J., Parker, M. M., Jaeschke, R. (2007). Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. <em>Intensive Care Medicine</em>, <em>34</em>(1), 17-60. https://doi.org/10.1007/s00134-007-0934-2</li>
</ol>
</article>